Is amiodarone an underrecognized cause of acute respiratory failure in the ICU?

Chest

Volumn 120, Issue 1, 2001, Pages 275-282

  Ashrafian, H ^a   Davey, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adult respiratory distress syndrome; Amiodarone; Cardiac surgery; Pulmonary toxicity

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DEETHYLAMIODARONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STEROID;

ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL FEATURE; DRUG INDUCED DISEASE; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; LUNG INJURY; LUNG TOXICITY; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TERMINALLY ILL PATIENT;

EID: 0034887125     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.1.275     Document Type: Article

References (72)

1. Evidence based analysis of amiodarone efficacy and safety
2. Amiodarone: Clinical trials
3. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
4. Amiodarone
5. Amiodarone pulmonary toxicity; recognition and pathogenesis (part I)
6. Amiodarone pulmonary toxicity; recognition and pathogenesis (part 2)
7. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues
8. Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone
9. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations
10. Amiodarone pneumonitis: Bronchoalveolar lavage findings in 15 patients and review of the literature
11. Effects of in vitro amiodarone exposure on alveolar macrophage inflammatory mediator production
12. Amiodarone lung: Pathologic findings in clinically toxic patients
13. Amiodarone pulmonary toxicity: Clinical, radiologic, and pathologic correlations
14. Mechanisms of amiodarone pulmonary toxicity
15. Clinical features of amiodarone-induced pulmonary toxicity
16. Amiodarone-associated pulmonary toxicity: A clinical and pathologic study of eleven cases
17. Mechanisms underlying variability in response to drug therapy: Implications for amiodarone use
18. Amiodarone pulmonary toxicity: Report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography
19. The environment and disease: Association or causation
20. Diffuse alveolar damage syndrome associated with amiodarone therapy
21. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new anti-arrhythmic drug treatment
22. Life-threatening postoperative pulmonary complications in patients with previous amiodarone pulmonary toxicity undergoing cardiothoracic operations
23. Fatal postoperative amiodarone pulmonary toxicity
24. Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?
25. Cardiopulmonary effects of chronic amiodarone therapy in the early postoperative course of cardiac surgery patients
26. Amiodarone-related postoperative adult respiratory distress syndrome
27. Acute respiratory distress syndrome
28. Amiodarone and the development of ARDS after lung surgery
29. Amiodarone and the development of ARDS after lung surgery
30. Acute amiodarone-induced lung toxicity
31. Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation
32. Amiodarone and the development of ARDS after lung surgery
33. Low-dose amiodarone-related complications after cardiac operations
34. Electro-cardiographic and antiarrhythmic effects of intravenous amiodarone: Results of a prospective, placebo-controlled study
35. Amiodarone prophylaxis for tachycardias after coronary artery surgery: A randomised, double blind, placebo controlled trial
36. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery
37. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery
38. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Rationale and protocol: CAMIAT Investigators
39. Cardiac arrest in Seattle: Conventional versus amiodarone drug evaluation (the CASCADE study)
40. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: European Myocardial Infarct Amiodarone Trial Investigators
41. Primum non nocere. Is the therapy worse than the disease?
42. The role of free radicals in the pathogenesis of amiodarone toxicity
43. Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture
44. Effect of amiodarone (AMD) on the antioxidant enzymes, lipid peroxidation and mitochondrial metabolism
45. Postoperative acute respiratory distress syndrome: A complication of amiodarone associated with 100% oxygen ventilation
46. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs
47. Free radicals and human disease
48. Perioperative serum levels of tumour-necrosis-factor α (TNF-α), IL-1β, IL-6, IL-10, and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for hemodilution
49. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: The role of tissue injury by surgical incision
50. Mechanisms of the systemic inflammatory response
51. Circulating endotoxin and cytokines after cardiopulmonary bypass: Differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes
52. Respiratory dysfunction after uncomplicated cardiopulmonary bypass
53. Multivesiculated macrophages: Their implication in fine-needle aspiration cytology of lung mass lesions
54. Amiodarone pulmonary toxicity: Cytopathology, ultrastructure, and immunocytochemistry
55. Clinical aspects of amiodarone pulmonary toxicity
56. Pulmonary accumulation of amiodarone and N-desethylamiodarone: Relationship to the development of pulmonary toxicity
57. Cytotoxicity of amiodarone in cultured human endothelial cells
58. Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages
59. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment
60. Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacologic characteristics
61. Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease
62. Comparison of the in vivo pulmonary toxicity of amiodarone and des-oxo-amiodarone in the hamster
63. Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro
64. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action
65. Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells
66. Bronchiolitis obliterans organizing pneumonia during low-dose amiodarone therapy
67. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80
68. Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis
69. Bronchiolitis obliterans organising pneumonia secondary to amiodarone treatment
70. Low-dose steroid therapy for prophlaxis of amiodarone-induced pulmonary infiltrates
71. Amiodarone associated alveolitis and polyarthropathy: Treatment by plasma exchange